The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...

The report, published as part of the National Program for Quality Indicators in Community Healthcare for 2023, points to the ...

An obesity expert weighs in on intriguing new data and new drugs that hold promise in the battle against a stubborn problem.

Discover how new weight loss drugs from Novo Nordisk (NVO) and Eli Lilly (LLY) may have helped reduce U.S. obesity rates.

Newly released data shows that the U.S. may have reached peak obesity in 2020 — and the timing unsurprisingly coincides with ...

WASHINGTON - Experts expressed enthusiasm after US health regulators approved the first new form of treatment for schizophrenia in decades. The drug, called Cobenfy and developed by US pharma ...

Over a long-enough period, new entrants ... illnesses like obesity or diabetes, if it ever happens. September has been an intense month so far for R&D dealmaking for genetic drugs.

Eli Lilly and Novo Nordisk are spending billions to find new ... like obesity or diabetes, if it ever happens. September has been an intense month so far for R&D dealmaking for genetic drugs.

A new drug has been approved for the treatment of schizophrenia in adults. On Thursday, the U.S. Food and Drug Administration (FDA) approved COBENFY (xanomeline and trospium chloride), an oral ...

People with schizophrenia will have a new treatment option for the first time in more than three decades, after the Food and Drug Administration Thursday approved a new kind of drug. Studies ...

British scientists have hailed the US approval of a new drug for schizophrenia, saying it “has the potential to change the lives of millions of people”. The “major advance” in treatment ...